SILCOPHL

Silco Pharmaceuticals Limited · Pharmaceuticals and Chemicals · Cat B

29/100

Weak

৳21.1

DSE Hexagon

Stands out for a solid balance sheet, held back by little dividend.

Six lenses, each scored 0–100 from the analysis. Integrity is DSE-specific — it reads how organic the price action is (high = clean, low = concentrated-operator risk). Descriptive only, not a recommendation.

Risks & rewards

Risks (1)

⚠ Earnings trending down

Rewards (1)

✓ Trades below estimated fair value

Score breakdown

Price history & performance

52-week high৳22.1

52-week low৳11.6

From 52w high-4.5%

Beta1.19

7D -3.7%

1M +5.5%

3M +42.6%

6M +57.5%

1Y +37.9%

YTD +54.0%

Shareholder returns vs DSEX

SILCOPHL+2.4%

DSEX+2.4%

SILCOPHL outperformed the DSEX since Jul 8, 2026 — that's when we started tracking the index, so this window will get longer over time.

Volatility

Annualized volatility33.9%

Daily VaR (95%)-3.05%

Max drawdown (5y)-67.1%

Correlation to market0.59

Typical volatility for a DSE stock. Descriptive only — past volatility is not a forecast.

Technical read

RSI (14)56.8

MACDbearish

Bollingerinside bands (-0.1σ)

Price cycle (Wyckoff)DIST

Health trendstable

Flow pressureaccumulation

Valuation

Fair value ()

Upside—

Dividend yield+0.50%

Fundamental verdictWATCH

Confidence—

Ownership

Institutional holding19.66%

Foreign holding0.0%

Free float45.07%

Sponsor, institutional, foreign and public holdings from the latest disclosed shareholding pattern. Descriptive only.

Share structure

Authorized capital৳1,050mn

Paid-up capital৳1,038.07mn

Face value৳10

Market lot1

Outstanding shares103,807,000

Last AGM19-01-2026

Fiscal year end30-Jun

Reserve & surplus (ex-OCI)৳1,350.7mn

Other comprehensive income৳1.2mn

Financials

Recent P/E ratio

DateCurrent P/ETrailing P/E

Jul 14, 2026 49.22 63.64

Jul 13, 2026 49.45 63.94

Jul 12, 2026 49.69 64.24

Jul 9, 2026 48.75 63.03

Jul 8, 2026 48.28 62.42

Jul 7, 2026 48.75 63.03

Based on the latest un-audited financial statements. Descriptive only.

Dividend history

20251.1%

20241%

20233%

20225%

202110%

202010%

20192%

Earnings & NAV

YearEPSNAVDividend

2025 0.41 23.02 1.10000002384186%

2024 0.44 22.66 1%

2023 0.67 22.35 3%

2022 0.81 21.95 5%

Quarterly EPS — FY2026

Q10.16

Q20.11

Half-year0.27

Q30.05

Nine-month0.32

From disclosed annual reports and dividend declarations. Descriptive only, not a forecast.

Levels

Resistance

৳21.3

৳22.1

৳23.3

৳24

Support

৳21

৳20.2

৳19

৳18.4

Historical bounce zones

Apr 30, 2025: ৳12.6→৳15.4 +22%

May 28, 2025: ৳13→৳15.8 +22%

Jun 22, 2025: ৳13.6→৳17.7 +30%

Sep 11, 2025: ৳15.7→৳18.5 +18%

Nov 16, 2025: ৳11.1→৳14.4 +30%

Dec 9, 2025: ৳12.3→৳14.2 +15%

Mar 9, 2026: ৳12.5→৳15.7 +26%

Apr 28, 2026: ৳13.9→৳22.6 +63%

Sector peers

Other Pharmaceuticals and Chemicals names, ranked by our analysis score (DSE has no market-cap feed). Descriptive comparison only.

ScripScorePriceUpsideYield

IBNSINAThe IBN SINA Pharmaceutical Industry PLC 87 ৳326.5 +12.00% +2.00%MARICOMarico Bangladesh Limited 87 ৳2,732.4 +24.00% +2.20%SQURPHARMASquare Pharmaceuticals PLC. 85 ৳221.4 +120.00% +5.40%ACMELABThe ACME Laboratories Limited 79 ৳86.9 +138.00% +4.10%BXPHARMABeximco Pharmaceuticals PLC. 78 ৳153.2 +54.00% +2.60%RENATARenata PLC 64 ৳464.3 -25.00% +1.20%

Historical outlook

Based on how similar setups behaved historically — not a prediction of what will happen.

10-day 40% vs 40% market avg Typical move: -5.2% / -0.9% / 4.3%

30-day 41% vs 42% market avg Typical move: -9.5% / -1.6% / 7.7%

Signals: Double Top

Reference levels

Descriptive reference points from the analysis — not instructions to buy or sell.

Entry readWAIT (until clears both axes)

Reference stopn/a

Reference target—

Timing notewatch; no fresh money

Elevated (score 120) — acceptable only with real earnings and sponsor backing; artificial-activity lens applies. Phase: DORMANT (38% >200-MA, flow neut). Elevated sharp-fall risk 12%. Balance sheet RECOVERING (Z rising). [fundamentals WATCH, payout 27.0%, yield 0.5%]